Halozyme - HALO Operating profit EBITDA
Risks associated with dependence on a narrow circle of partners and patents are evident in the trend of total EBITDA, where the metric stands at 1160.67. Halozyme Therapeutics (HALO) revenues are based on a unique drug delivery method that generates multi-year passive income. High R&D costs and regulatory barriers create a robust moat for the business against new market entrants.
Halozyme Therapeutics, Inc. (HALO) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Halozyme Therapeutics|HALO - Long-Term Debt to Capital|Short-Term Debt to Capital Halozyme Corp|HALO - Company Debts|Debt to Book Capitalization Ratio Halozyme Therapeutics|HALO - Company Long-Term Debt|Short-Term Debt Halozyme|Critical Liquidity Ratio halozyme.com
- earnings and market ratios statistics:
HALO - Net Income|Expected Net Profit Halozyme Therapeutics|HALO - Price to Earnings Ratio|Projected Price to Earnings Halozyme|HALO - PEG Multiple|Company Value to EBITDA Halozyme Inc.|HALO - Operating profit before deduction of amortization|Earnings per share for the trailing year Halozyme|HALO - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months halozyme.com|HALO - Earnings growth in current year|Expected earnings per share trend next year Halozyme Therapeutics
- sales revenue and business income indicators:
Analysis of all company metrics:halozyme.com (HALO)
This indicator measures the amount of cash generated by the core business before deducting interest and amortization. Rising values demonstrate the company's ability to service debt and fund expansion. By analyzing the company's operating result before depreciation and amortization, an investor assesses the real efficiency of operational activities. This trend directly depends on the scaling of licensing payments. For Halozyme Therapeutics (HALO), this reflects the monetization of the ENHANZE platform through royalties.
Competitors of Halozyme Therapeutics (HALO)
Operating profit EBITDA beigene.com ONC|RVMD: Operating profit before deduction of amortization|AAPG - Operating profit EBITDA|CG Oncology Corp (CGON) - Profit before payment of interest, taxes and amortization|UroGen - Income before deduction of interest, taxes and amortization|BCAX (Bicara Therapeutics Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization personalis.com PSNL|Operating profit EBITDA ERAS|Delcath Systems - Operating profit before amortization|Y-mAbs Therapeutics Inc - Operating profit before deduction of amortization|Operating profit EBITDA Aura Corp AURA|CADL - Profit before payment of interest, taxes and amortization|Accuray (ARAY) - Operating profit before deduction of amortization|SLS: Operating profit EBITDA|Actuate Therapeutics (ACTU) - Operating profit EBITDA|Operating profit before deduction of amortization CTOR|HURA: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Protara Therapeutics (TARA)|Company profit before taxes, interest and amortization FATE|Operating profit EBITDA WHWK (aadibio.com)|Company profit before taxes, interest and amortization TCRX (TScan)|CSBR - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization XBIT (XBiotech Inc)|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization OSTX (OS Therapies Incorporated)|Profit before payment of interest, taxes and amortization Radiopharm Theranostics Ltd|Profit before interest, taxes and amortization Artiva Biotherapeutics ARTV|Operating profit EBITDA ANL|VERU - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Profit before interest, taxes and amortization|RENB: Operating profit before deduction of amortization|Operating profit before depreciation charges Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Operating profit before deduction of amortization Curis, Inc. (CRIS)|Operating profit EBITDA APLM|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (advanbiomed.com)|GNPX - Operating profit before deduction of amortization|CLDI: Operating profit before deduction of amortization|SBFM - Operating profit EBITDA|Xenetic Biosciences (XBIO) - Profit before payment of interest, taxes and amortization|SLRX: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization American Oncology Network, Inc. AONC|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics|Elevation Oncology, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA iCAD, Inc. ICAD|Ikena Oncology, Inc. - Operating profit EBITDA|NTBL - Operating profit EBITDA|VIRX (Viracta Therapeutics) - Operating profit before deduction of amortization|MorphoSys AG - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences Corp) - Operating profit EBITDA|Operating profit EBITDA Ascentage Pharma Group International
